Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cytokinetics Inc (CYTK): Mark Lampert’s Biotechnology Value Fund Loads Up On More Shares

Page 1 of 14

Mark Lampert‘s Biotechnology Value Fund has filed a Form 13G on Cytokinetics, Inc. (NASDAQ:CYTK), one of its top-10 holdings at the end of 2015. The filing reveals an increase of nearly 1.00 million shares to the fund’s holding since then, lifting it to 3.91 million shares and ownership of just over 10% of the company’s stock. The full content of the filing can be found below.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Trading Fund OS 0 342,985 0 342,985 342,985 Less than 1%
BVF Partners OS Ltd 0 342,985 0 342,985 342,985 Less than 1%
BVF Partners 0 3,908,329 0 3,908,329 3,908,329 10.1%
BVF Inc 0 3,908,329 0 3,908,329 3,908,329 10.1%
Mark N. Lampert 0 3,908,329 0 3,908,329 3,908,329 10.1%
Mark Lampert
Mark Lampert
Biotechnology Value Fund / BVF Inc

Page 1 of 14 SEC Filing

Washington, D.C. 20549
(Rule 13d-102)


(Amendment No. 3)1
Cytokinetics, Incorporated
 (Name of Issuer)
Common Stock, $0.001 par value per share
 (Title of Class of Securities)
23282W 60 5
 (CUSIP Number)
March 1, 2016
 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   o  Rule 13d-1(b)
   x  Rule 13d-1(c)
   o  Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
      The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Cytokinetics Inc (NASDAQ:CYTK)
Trade (NASDAQ:CYTK) Now!
Page 1 of 14

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!